Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

5th World Congress on Cancer Therapy

Atlanta, USA

Chaymaa Marouf

University Hassan II Ain Chock, Morocco

Title: Analysis of APOBEC3 and driver genes polymorphisms in Moroccan patients with breast cancer

Biography

Biography: Chaymaa Marouf

Abstract

Breast cancer (BC) is the most prevalent cancer in women and a major public health problem in Morocco. Several Moroccan studies have focused on studying this disease, but more are needed, especially at the genetic and molecular levels. Th erefore, we investigated a number of tumor suppressor genes commonly mutated in sporadic breast cancer.In this case-control study, we examined 37 single nucleotide polymorphisms (SNPs) in 13 genes (APOBEC3A, APOBEC3B, ARID1B, ATR, MAP3K1, MLL2, MLL3, NCOR1, RUNX1, SF3B1, SMAD4, TBX3, TTN), which were located in the core promoter, 5´-and 3´UTR or which were nonsynonymous SNPs to assess their potential association with inherited predisposition to breast cancer development. A total of 226 Moroccan BC cases and 200 matched healthy controls were included in this study. Th e analysis showed that 12 SNPs in 8 driver genes, 4 SNPs in APOBEC3B gene and 1 SNP in APOBEC3A gene were associated with BC risk and/or clinical outcome at p≤0.05 level. RUNX1_rs8130963 (OR= 2.25; 95% CI 1.42-3.56; P = 0.0005), TBX3_rs8853 (OR= 2.04; 95% CI 1.38- 3.01; P = 0.0003), TBX3_rs1061651 (OR= 2.14; 95% CI 1.43-3.18; P = 0.0002), TTN_rs12465459 (OR= 2.02; 95% CI 1.33-3.07; P = 0.0009), were the most signifi cantly associated SNPs with BC risk. A strong association with clinical outcome were detected for the genes SMAD4 _rs3819122 (OR= 0.45; 95% CI 0.25-0.82; P = 0.009) and TTN_rs2244492 (OR= 0.45; 95% CI 0.25-0.82; P = 0.009). Our results suggest that genetic variation in driver genes is associated with the risk of BC and may have impact on clinical outcome. Th ese preliminary fi ndings require replication in larger studies.